Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2024-02-01 Sale |
2024-02-02 9:35 pm |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $16.18 | $647,200 | 236,321 (Direct) |
View |
2024-01-29 Sale |
2024-01-30 7:00 pm |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $14.09 | $563,600 | 276,321 (Direct) |
View |
2024-01-22 Sale |
2024-01-24 5:00 pm |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $12.31 | $492,508 | 215,300 (Direct) |
View |
2022-07-18 Sale |
2022-07-21 4:30 pm |
Cullinan Oncology Inc. | CGEM | Savill Corrine Acting Chief Business Officer |
20,000 | $15.18 | $303,593 | 149,615 (Direct) |
View |
2022-07-11 Sale |
2022-07-12 4:14 pm |
Cullinan Oncology Inc. | CGEM | Savill Corrine Acting Chief Business Officer |
40,000 | $13.33 | $533,304 | 169,615 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2025-02-19 Option Award |
2025-02-21 6:00 pm |
N/A 2035-02-19 |
Cullinan Therapeutics Inc. | CGEM | Savill Corrine Chief Business Officer |
112,500 | $0 | 315,990 (Direct) |
View |
2024-02-22 Option Award |
2024-02-23 5:00 pm |
N/A 2034-02-22 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
112,500 | $0 | 278,490 (Direct) |
View |
2024-02-01 Exercise |
2024-02-02 9:35 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $4.3 | 236,321 (Direct) |
View |
2024-02-01 Exercise |
2024-02-02 9:35 pm |
N/A 2030-10-31 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $0 | 236,321 (Direct) |
View |
2024-01-29 Exercise |
2024-01-30 7:00 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $4.3 | 276,321 (Direct) |
View |
2024-01-29 Exercise |
2024-01-30 7:00 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
40,000 | $0 | 276,321 (Direct) |
View |
2024-01-22 Exercise |
2024-01-24 5:00 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
35,875 | $4.3 | 215,300 (Direct) |
View |
2024-01-22 Exercise |
2024-01-24 5:00 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
35,875 | $0 | 215,300 (Direct) |
View |
2023-02-17 Option Award |
2023-02-21 6:57 pm |
N/A 2033-02-16 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Chief Business Officer |
61,500 | $0 | 211,115 (Direct) |
View |
2022-02-11 Option Award |
2022-02-15 4:43 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Acting Chief Business Officer |
49,500 | $0 | 242,615 (Direct) |
View |
Ownership |
2021-01-07 8:29 pm |
N/A N/A |
Cullinan Management Inc. | CGEM | Savill Corrine Acting Chief Business Officer |
0 | $0 | 379,321 (Direct) |
View |